New drug aims to shrink hard-to-treat tumors

NCT ID NCT07612189

Recruiting now Disease control Sponsor: NEOK Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called NEOK002 in people with advanced solid tumors that have spread and cannot be removed by surgery. The drug is designed to target two proteins on cancer cells to deliver a toxic payload. The study has two parts: first, finding the safest dose, and then, checking if the drug can shrink tumors. About 155 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS

Contacts and locations

Locations

MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10065, United States
NEXT Oncology
NOT_YET_RECRUITING

Austin, Texas, 78758, United States
NEXT Oncology
NOT_YET_RECRUITING

Dallas, Texas, 78299, United States
NEXT Oncology
NOT_YET_RECRUITING

Houston, Texas, 77054, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 75039, United States
NEXT Oncology
NOT_YET_RECRUITING

Fairfax, Virginia, 22031, United States
SCRI Oncology Partners
NOT_YET_RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.